Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Is aged 4 to 16 years, inclusive (Latin America) or 4 to 8 years, inclusive (Asia).~2. Are in good health at the time of entry into the study as determined by medical history, physical examination (including vital signs), and clinical judgment of the investigator.~Main Exclusion Criteria:~1. Febrile illness (body temperature ≥38°C) or moderate or severe acute illness or infection at the time of enrolment.~2. History or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose an additional risk to the participant due to participation in the study.~3. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccines within 28 days after Day 1 (Month 0).~4. Previous participation in any clinical study of a dengue candidate vaccine, or previous receipt of any dengue vaccines (investigational or licensed).

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Tetravalent Dengue Vaccine (TDV) 0.5 mL (Type: EXPERIMENTAL): TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).